GURUFOCUS.COM » STOCK LIST » Asia » Hong Kong » HKSE » Ocumension Therapeutics (HKSE:01477) » Definitions » Net Income Including Noncontrolling Interests
Switch to:

Ocumension Therapeutics (HKSE:01477) Net Income Including Noncontrolling Interests

: HK$-459.0 Mil (TTM As of Jun. 2022)
View and export this data going back to 2020. Start your Free Trial

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Ocumension Therapeutics's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2022 was HK$-225.8 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2022 was HK$-459.0 Mil.

Ocumension Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Ocumension Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Net Income Including Noncontrolling Interests
-237.87 -1,474.93 -2,684.85 -318.35

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Net Income Including Noncontrolling Interests Premium Member Only Premium Member Only Premium Member Only -1,906.19 -620.10 -84.09 -233.12 -225.85

Ocumension Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-459.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Ocumension Therapeutics logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
HKSE:09966 HKSE:02257 HKSE:02171 HKSE:02696 HKSE:09939 HKSE:02162 HKSE:01952 HKSE:02616 HKSE:00775 HKSE:01167 OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122
Traded in Other Exchanges
5DG:Germany
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Website
http://www.ocumension.com
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines